TTR and hepatitis B virus infection: In addition to these, other first and second generation siRNA-LNP programs entered clinical trials through the early to mid-2010s (e.g., DCR-MYC for cancer, TKM-100201 and TKM-100802 for Ebola, and TKM-HBV for hepatitis B infection) [66], including in 2010, a first-generation LNP formulation known as ALN-TTR01, which entered Phase 1 clinical study in patients with transthyretin (TTR) mediated amyloidosis.